Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?

PURPOSE: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It is not universally effective, however; although to date it is not possible to predict with any accuracy which patients will respond to treatment. The aim of this ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Hider, S L, Silman, A J, Thomson, W, Lunt, M, Bunn, D, Symmons, D P M
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2009
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596302/
https://www.ncbi.nlm.nih.gov/pubmed/18292102
http://dx.doi.org/10.1136/ard.2008.088237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596302/
https://www.ncbi.nlm.nih.gov/pubmed/18292102
http://dx.doi.org/10.1136/ard.2008.088237

Ejemplares similares